Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Astragalus membranaceus-derived exosomes deliver calycosin to orchestrate the Nrf2/SLC7A11/GPX4 axis against ferroptosis in Parkinson's disease.

Created on 08 Nov 2026

Authors

Haihua Huang, Xiayu Xu, Xinyu Huo, Yixuan Bo, Huijie Fan, Lei Xu, Zhi Chai, Lixia Yang

Published in

Journal of ethnopharmacology. Pages 122612. Nov 07, 2026. Epub Nov 07, 2026.

Abstract

Astragalus membranaceus (Fisch.) Bunge (Fabaceae) is documented in Shennong's Classic of Materia Medica to treat Qi deficiency-induced cerebral blood stasis and limb tremor resembling Parkinson's disease (PD). Its primary bioactive component, calycosin (CA), exerts anti-ferroptosis effects; however, its ability to cross the blood-brain barrier (BBB) is severely limited. Herbal-derived exosomes isolated from Astragalus membranaceus act as homologous natural nanocarriers to overcome this limitation; however, the anti-PD efficacy and nuclear factor erythroid 2-related factor 2 (Nrf2)-dependent ferroptosis regulatory mechanism of Astragalus membranaceus-derived exosomes (AS-Exos) loaded with CA (AS-Exos-CA) remain unelucidated.
To construct AS-Exos-CA, verify both its BBB-crossing capacity and neuroprotective effect on dopaminergic neurons, and investigate whether its anti-ferroptosis protection relies on the Nrf2/SLC7A11/GPX4 axis, to provide modern pharmacological evidence for the ethnopharmacological application of Astragalus membranaceus against PD.
AS-Exos were isolated by ultracentrifugation and characterized using NTA and TEM. HPLC was employed to screen the optimal CA-loading ratio for preparing AS-Exos-CA and measure its encapsulation efficiency. PKH26 and DiR fluorescence labeling were used to assess cellular uptake and BBB penetration of AS-Exos-CA in PC12 cells and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mice, respectively. Motor function, dopaminergic neuron survival, ferroptosis-related oxidative stress, iron metabolism and mitochondrial ultrastructure were assessed to evaluate the therapeutic effects of AS-Exos-CA in MPTP-induced PD mice. 1-methyl-4-phenylpyridinium ion (MPP+)-injured PC12 cells combined with the Nrf2-specific inhibitor ML385 were used to verify the Nrf2-dependent mechanism mediating AS-Exos-CA-derived protection.
AS-Exos-CA displayed typical vesicle morphology, was efficiently taken up by PC12 cells, and significantly accumulated in mouse brain 12 h after intravenous injection. Compared with free CA and AS-Exos, AS-Exos-CA more effectively ameliorated motor deficits, rescued dopaminergic neurons, mitigated mitochondrial injury and iron deposition, restored glutathione (GSH), and lowered malondialdehyde (MDA) and reactive oxygen species (ROS) levels. AS-Exos-CA facilitated Nrf2 nuclear translocation and up-regulated the downstream expression of SLC7A11 and GPX4. ML385 abolished its in vitro anti-ferroptotic actions, verifying the essential role of Nrf2 signaling.
AS-Exos serve as homologous herbal nanocarriers, enhancing CA penetration across the BBB for brain delivery. AS-Exos-CA exerts robust neuroprotection against PD largely by inhibiting neuronal ferroptosis via the Nrf2/SLC7A11/GPX4 pathway. This herbal exosome-based nanoformulation overcomes the biocompatibility limitations of synthetic nanomaterials and represents a promising disease-modifying strategy for PD, thereby advancing the modern investigation of Qi-tonifying herbal medicines in degenerative central nervous system (CNS) disorders.

PMID:
42998702
Bibliographic data and abstract were imported from PubMed on 08 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 34
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement